biib131
Small moleculeexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
1
Phase 4
0
Earliest trial started Dec 1, 2023 (NCT05764122)
Timeline
2020s
- Jan 1, 2023
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- UnclearUnclear
Unclear unclear
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06990867 | Phase 2/Phase 3 (Phase 3) | May 15, 2025 | Ji Xing Pharmaceuticals (Shanghai) Co., Ltd. |
| NCT05764122 | Phase 2 | Dec 1, 2023 | Biogen |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Biogen | For profit | 1 | 1 | 1 | 2023 |
| Ji Xing Pharmaceuticals (Shanghai) Co., Ltd. | For profit | 1 | 1 | 1 | 2025 |
2 organizations
Page 1 / 1